News

In this special bonus session from the 2021 ALS Canada Research Forum, Dr. Martin Duennwald, from Western University, gave a talk entitled “Hsp90 and its co-chaperones modulate protein misfolding in ALS.” You will also have the chance to…

Dr. David Taylor, VP of Research, hosted a webinar on June 15, 2021 exploring the current state of clinical trials globally and in Canada, where he also addressed some key questions around specific studies and clinical trials in…

We are pleased to extend a warm welcome to Alyssa Barry, Ken Chan, Elizabeth Gandolfi and Dr. Angela Genge who recently joined the ALS Canada Board of Directors. Alyssa Barry became connected to the ALS community when her uncle was…

Welcome to ALS Canada’s first Advocacy Update. This new blog series is a place for the ALS community to learn about and stay updated on ALS Canada’s advocacy efforts as well as relevant developments within government.  Please note that because…

With deep appreciation for their contributions of time and expertise, we thank Carol Cottrill, Daniel Riverso and Vincent Quinn whose terms on the ALS Canada Board of Directors have come to an end, and Josette Melanson who becomes Past Chair…

ALS Canada and Brain Canada join forces with Alnylam Pharmaceuticals and Regeneron to support a collaborative platform that will unite ALS researchers and accelerate breakthroughs. Together, Brain Canada and ALS Canada are pleased to announce the awarding of a $2,850,000 2019…

ALS may not be considered rare by all. But the community of approximately 3,000 Canadians living with the disease today is small enough to face unique challenges, with access to therapies – from clinical trial to reimbursement – being a…

Toronto – Sustained investment in transformative research is vital to unlocking the mysteries around the causes and progression of ALS, a devastating terminal disease that gradually paralyzes people because the brain is no longer able to communicate with the muscles of…